Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074986 | 0.92 | MEN1 (0.52) | L3MBTL1MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL7502314 | 0.91 | MAPK1 (0.56) | L3MBTL1MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL1570844 | 0.88 | MEN1 (0.57) | L3MBTL1MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL23055438 | 0.86 | MEN1 (0.55) | L3MBTL1MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL8522162 | 0.86 | SMN1; SMN2 (0.56) | L3MBTL1MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL5778191 | 0.85 | MEN1 (0.53) | L3MBTL1MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL9358195 | 0.84 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL9358190 | 0.84 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL18123325 | 0.84 | SMN1; SMN2 (0.49) | L3MBTL1MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL2926092 | 0.83 | ALDH1A1 (0.45) | L3MBTL1MEN1KMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 506 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110577515-B | Synthesis method of 4- (azetidin-3-yl) -1-methylpiperazine-2-one dihydrochloride | 南通大学 | 2022-05-17 | — | — | CN | claimed |
| CN-110577515-A | Synthesis method of 4- (azetidin-3-yl) -1-methylpiperazine-2-one dihydrochloride | 南通大学 | 2019-12-17 | — | — | CN | claimed |
| EP-1133489-B9 | ISONIPECOTAMIDES FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1133489-B1 | ISONIPECOTAMIDES FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1533310-A1 | Isonipecotamides for the treatment of integrin-mediated disorders | Ortho-McNeil Pharmaceutical, Inc. (US) | 2005-05-25 | — | — | EP | claimed |
| US-20030181440-A1 | Isonipecotamides for the treatment of integrin-mediated disorders | COSTANZO MICHAEL J (US) | 2003-09-25 | — | — | US | claimed |
| EP-1133489-A1 | ISONIPECOTAMIDES FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-09-19 | — | — | EP | claimed |
| WO-2001023376-A1 | ISONIPECOTAMIDES FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-04-05 | — | — | WO | claimed |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12509454-B2 | Thiadiazolyl derivatives | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12391690-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LIGACHEM BIOSCIENCES INC. (KR) | 2025-08-19 | — | — | US | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| EP-4587126-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2025-07-23 | — | — | EP | disclosed |
| WO-2000001702-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1998046591-A1 | SELECTIVE FACTOR Xa INHIBITORS | COR THERAPEUTICS, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| EP-0199096-B1 | NITRO SUBSTITUTED HETEROARYL COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1989-12-20 | — | — | EP | disclosed |
| EP-0199096-A1 | Nitro substituted heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-10-29 | — | — | EP | disclosed |
| US-4619927-A | Novel nitropyrazinyl- and nitropyridinyl- substituted piperazin-3-one and hexahydro-1H-1,4-diazepin-5-one compounds useful as adjuncts to radiation therapy | MERCK & CO., INC. (US) | 1986-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | L3MBTL1 1234/4885MEN1 4795/4885KMT2A 2910/4885 |
| US-12391690-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | ENPP2, PLA2G10, LPCAT1 | L3MBTL1 3027/4885MEN1 1247/4885KMT2A 1905/4885 |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | L3MBTL1 95/4885MEN1 3261/4885KMT2A 4018/4885 |
| US-12509454-B2 | Thiadiazolyl derivatives | POLD1, POLQ, DNA2 | L3MBTL1 3784/4885MEN1 3388/4885KMT2A 2518/4885 |
| US-20030181440-A1 | Isonipecotamides for the treatment of integrin-mediated disorders | ITGB2, ITGA1, ITGB1 | L3MBTL1 2725/4885MEN1 3494/4885KMT2A 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.